Article

Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator.

University of Toronto, Toronto Western Hospital, Department of Medicine, Division of Neurology, 399 Bathurst Street, 5th Floor, West Wing, room 443, Toronto, Ontario M5T 2S8, Canada.
Stroke (Impact Factor: 6.16). 02/2011; 42(4):1041-5. DOI: 10.1161/STROKEAHA.110.599183
Source: PubMed

ABSTRACT Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7. However, evidence to date has been derived from a small single-center cohort of patients.
We used data from Phase 3 of the Registry of the Canadian Stroke Network. We compared the rates of post-tissue plasminogen activator hemorrhage, including any intracerebral hemorrhage, symptomatic intracerebral hemorrhage, and gastrointestinal hemorrhage in patients with and without preadmission warfarin use. For those receiving warfarin, we restricted the analysis to patients with an international normalized ratio <1.7 on presentation. Secondary outcomes included functional status and mortality. Multivariate analyses were performed to adjust for other prognostic factors.
Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 (7.2%) were receiving warfarin before admission and had an international normalized ratio <1.7. Preadmission warfarin use was not associated with any secondary intracerebral hemorrhage (OR, 1.2; 95% CI, 0.7 to 2.2), symptomatic intracerebral hemorrhage (OR, 1.1; 95% CI, 0.5 to 2.3), or gastrointestinal hemorrhage (OR, 1.1; 95% CI, 0.2 to 5.6). Multivariate analysis showed that preadmission warfarin use was independently associated with a reduced risk of poor functional outcome (OR, 0.6; 95 CI, 0.3 to 0.9), but not with in-hospital mortality (OR, 0.6; 95% CI, 0.3 to 1.0).
The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.

0 Bookmarks
 · 
89 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: This article reviews some of the current literature in support or against extension of the intravenous tissue plasminogen activator window, use of intra-arterial therapy or devices, as well alternative pharmacologic therapies that may extend the window for treatment of patients with acute ischemic stroke, with consideration of the relative risk of thrombolytic complications, factors for worse outcomes, and unclear stroke onset, as seen in patients with wake-up stroke. The issue of newer concomitant antithrombotic therapies as they affect the decision for acute ischemic stroke thrombolytic therapy is also explored.
    Neurologic Clinics 08/2013; 31(3):677-704. · 1.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Controversy surrounds the safety of intravenous (IV) tissue plasminogen activator (tPA) in ischemic stroke patients treated with warfarin. The European tPA license precludes its use in anticoagulated patients altogether. American guidelines accept IV tPA use with an international normalized ratio (INR) ≤1.7. The influence of warfarin on symptomatic intracerebral hemorrhage (SICH), arterial recanalization and long-term functional outcome in stroke thrombolysis remains unclear. Methods: We analysed data from 45074 patients treated with IV tPA enrolled in the SITS International Stroke Thrombolysis Register. 768 patients had baseline warfarin treatment with INR≤1.7. Outcome measures were SICH, arterial recanalization, mortality and functional independence at 3 months. Results: Patients on warfarin with INR≤1.7 were older, had more co-morbidities, and more severe strokes compared to patients without warfarin. There were no significant differences between patients with and without warfarin in SICH rates (adjusted odds ratio (aOR) 1.23 (95% CI 0.72-2.11) per SITS-MOST, 1.26 (0.82-1.70)) per ECASS II after adjustment for age, stroke severity and co-morbidities. Neither did warfarin independently influence mortality, aOR 1.05 (0.83-1.35), nor functional independence at 3 months, aOR 1.01 (0.81-1.24). Arterial recanalization by CT/MR angiography trended higher in warfarin patients, 62% (37/59) vs. 55% (776/1475), p=0.066. Recanalization approximated by disappearance at 22-36 hours of a baseline hyperdense middle cerebral artery sign was increased 63% (124/196) vs 55% (3901/7099), p=0.022. Interpretation: Warfarin treatment with INR≤1.7 did not increase the risk for SICH or death, and had no impact on long-term functional outcome in patients treated with intravenous tPA for acute ischemic stroke. ANN NEUROL 2013. © 2013 American Neurological Association.
    Annals of Neurology 06/2013; · 11.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Systemic thrombolysis with alteplase is the only approved medical treatment for patients with acute ischaemic stroke. Thrombectomy is also increasingly used to treat proximal occlusions of the cerebral arteries, but has not shown superiority over systemic thrombolysis with alteplase. Many patients with acute ischaemic stroke are pretreated with antiplatelet or anticoagulant drugs, which can increase the bleeding risk of thrombolysis or thrombectomy. Pretreatment with aspirin monotherapy increases the bleeding risk of alteplase in both observational and randomised trials with no effect on clinical outcome, and the risk of intracerebral haemorrhage is increased with the combination of aspirin and clopidogrel. Antiplatelet drugs should not be given in the first 24 h after alteplase treatment. Data from pooled randomised trials and a large observational study show that thrombolysis can probably be done safely in patients given vitamin-K antagonists if the international normalised ratio is less than 1·7, although bleeding risk is slightly raised. Almost no data are available for the safety of alteplase in patients with atrial fibrillation who have been given novel oral anticoagulants (NOAC) for stroke prevention. Some coagulation parameters could help to identify patients treated with NOAC who might be eligible for thrombolysis. Thrombectomy can be done in patients given antiplatelets and probably in those given anticoagulants; however, conclusions about anticoagulants are based on findings from observational studies with small patient numbers.
    The Lancet Neurology 05/2013; · 23.92 Impact Factor

Full-text

View
28 Downloads
Available from
May 16, 2014